Fig.4

Responsiveness Analysis Summary** of QLU-C10D across Four Lux-Lung Trial Datasets (LL1, LL3, LL5, LL8) in Detecting Change in Progressive Subjects, Treatment Arms, Adverse Events Groups, and Response Groups (stable vs. progressive), and Relative Responsiveness Compared to EQ-5D-3L Using Six Country-Specific Value Sets (Australia, Canada, Italy, the Netherlands, Poland, and the United Kingdom). t-test (all country value sets = 6 per cell) with Bonferroni-Holm corrected p-values: n. s. = not significant (p > .05), sig. = significant (p ≤ .05); “Diff.” = ES-QLU-C10D minus ES-EQ-5D-3L (Differences in Effect Sizes (ES) of QLU-C10D and EQ-5D3L country value set pairs); positive differences favor QLU-C10D, negative differences favor EQ-5D-3L;DRI difference responsiveness index (RI), SRM standardized response mean, RE (Relative Efficiency) = t-value-QLU-C10D divided by t-value-EQ-5D-3L; RE < 1 favors EQ-5D-3L, RE > 1 favors QLU-C10D; † Progressive Patients (LL1 + LL8): change from baseline to date of progression + /- 4 weeks; All Treat. = pooled data of all treatments (Afatinib monotherapy, Afatinib combinations, etc.); Afatinib = pooled data of Afatinib monotherapy; * [Treatment / Control]: LL1 [Afatinib monotherapy / placebo], LL3 [Afatinib / chemotherapy (Cisplatin + Pemetrexed)], LL5 [Afatinib + Paclitaxel / single-agent chemotherapy], LL8 [Afatinib / Erlotinib]. ** Detailed results are presented in Appendix B – E.